PTGX

PN-943 (α4β7-Integrin Antagonist)

Ulcerative Colitis (UC)

Phase 2 (Data)

Exp Date

TBA

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: PN-943 (α4β7-Integrin Antagonist) for Ulcerative Colitis (UC) - Phase 2 Data

  • ClinicalTrials.gov (NCT04504383): PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)


WHAT IS THE CATALYST EVENT?

  • Phase 2 Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBA


PRIOR DATA/EVENTS

PRESS RELEASE

MECHANISM OF ACTION

  • PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in clinical development for the treatment of inflammatory bowel disease. PN-943 is designed to offer the convenience of oral administration and the potential for improved safety and tolerability compared to antibody therapeutics administered by injection that target the alpha-4-beta-7 integrin pathway. PTG-100, a PN-943 analog, showed evidence of clinical and histological remission in patients with ulcerative colitis. PN-943 has completed Phase 1 development, demonstrating sustained target engagement with two weeks of daily administration.

MARKET

  • In 2015, an estimated 1.3% of US adults (3 million) reported being diagnosed with IBD (either Crohn’s disease or ulcerative colitis). This was a large increase from 1999 (0.9% or 2 million adults).

  • Learn more at CDC.gov

Updated by HC

PRTK, Ulcerative Colitis (UC), inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in your digestive tract, PN-943 (α4β7-Integrin Antagonist)

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon